Rhythm Pharmaceuticals, Inc. (RYTM): Price and Financial Metrics


Rhythm Pharmaceuticals, Inc. (RYTM): $7.59

-0.37 (-4.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RYTM POWR Grades


  • RYTM scores best on the Growth dimension, with a Growth rank ahead of 50.53% of US stocks.
  • The strongest trend for RYTM is in Quality, which has been heading up over the past 161 days.
  • RYTM ranks lowest in Quality; there it ranks in the 6th percentile.

RYTM Stock Summary

  • Rhythm Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 6.44% of US listed stocks.
  • RYTM's price/sales ratio is 304.54; that's higher than the P/S ratio of 98.72% of US stocks.
  • As for revenue growth, note that RYTM's revenue has grown 3,720% over the past 12 months; that beats the revenue growth of 99.66% of US companies in our set.
  • Stocks that are quantitatively similar to RYTM, based on their financial statements, market capitalization, and price volatility, are ETON, OVID, TGTX, LBRDA, and SGBX.
  • RYTM's SEC filings can be seen here. And to visit Rhythm Pharmaceuticals Inc's official web site, go to www.rhythmtx.com.

RYTM Valuation Summary

  • RYTM's price/sales ratio is 2114.9; this is 18533.48% higher than that of the median Healthcare stock.
  • RYTM's EV/EBIT ratio has moved up 15.3 over the prior 48 months.
  • RYTM's price/sales ratio has moved NA NA over the prior 48 months.

Below are key valuation metrics over time for RYTM.

Stock Date P/S P/B P/E EV/EBIT
RYTM 2021-08-31 2114.9 1.9 -10.8 -13.5
RYTM 2021-08-30 2066.0 1.8 -10.6 -13.2
RYTM 2021-08-27 2108.4 1.9 -10.8 -13.5
RYTM 2021-08-26 1984.8 1.7 -10.2 -12.6
RYTM 2021-08-25 2028.5 1.8 -10.4 -12.9
RYTM 2021-08-24 2017.2 1.8 -10.3 -12.8

RYTM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RYTM has a Quality Grade of F, ranking ahead of 2.46% of graded US stocks.
  • RYTM's asset turnover comes in at 0.004 -- ranking 418th of 681 Pharmaceutical Products stocks.
  • EVOK, ATRA, and EVFM are the stocks whose asset turnover ratios are most correlated with RYTM.

The table below shows RYTM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.004 0.728 -0.232
2021-06-30 0.001 0.544 -0.211
2021-03-31 0.000 0.886 -0.196
2020-12-31 0.000 NA -0.922
2020-09-30 0.000 NA -0.718
2020-06-30 0.000 NA -0.784

RYTM Price Target

For more insight on analysts targets of RYTM, see our RYTM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $36.67 Average Broker Recommendation 1.71 (Moderate Buy)

RYTM Stock Price Chart Interactive Chart >

Price chart for RYTM

RYTM Price/Volume Stats

Current price $7.59 52-week high $43.26
Prev. close $7.96 52-week low $7.55
Day low $7.55 Volume 265,369
Day high $8.45 Avg. volume 305,851
50-day MA $10.29 Dividend yield N/A
200-day MA $15.18 Market Cap 381.53M

Rhythm Pharmaceuticals, Inc. (RYTM) Company Bio


Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was founded in 2008 and is based in Boston, Massachusetts.


RYTM Latest News Stream


Event/Time News Detail
Loading, please wait...

RYTM Latest Social Stream


Loading social stream, please wait...

View Full RYTM Social Stream

Latest RYTM News From Around the Web

Below are the latest news stories about Rhythm Pharmaceuticals Inc that investors may wish to consider to help them evaluate RYTM as an investment opportunity.

Rhythm Pharmaceuticals: PDUFA Ahead, But Commercialization Concerns Remain

No summary available.

Seeking Alpha | January 15, 2022

Dosing underway in Rhythm Pharma''s setmelanotide trial for rare genetic disease of obesity

Rhythm Pharmaceuticals <> announces the first patient has been dosed with setmelanotide, the companys melanocortin-4 receptor (MC4R) agonist, in Phase 2 DAYBREAK clinical trial

Seeking Alpha | January 13, 2022

Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK and Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity

-- DAYBREAK is the most comprehensive Phase 2 trial ever initiated in rare genetic diseases of obesity ---- DAYBREAK is evaluating setmelanotide in patients with severe obesity and hyperphagia caused by variants in one of 31 pre-identified genes ---- First patient also dosed in Phase 3 switch trial evaluating a weekly formulation of setmelanotide -- BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to tra

Yahoo | January 13, 2022

Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up to $9.64

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) gapped up prior to trading on Monday . The stock had previously closed at $9.64, but opened at $10.16. Rhythm Pharmaceuticals shares last traded at $10.16, with a volume of 6 shares trading hands. A number of research analysts have commented on the stock. The Goldman Sachs Group upgraded shares of [] The post Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up to $9.64 appeared first on ETF Daily News .

ETF Daily News | December 22, 2021

Zacks: Analysts Anticipate Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to Announce -$1.00 EPS

Wall Street analysts expect Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) to announce earnings per share (EPS) of ($1.00) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Rhythm Pharmaceuticals earnings, with estimates ranging from ($1.08) to ($0.91). Rhythm Pharmaceuticals reported earnings per share of ($0.79) during the same quarter last year, []

Transcript Daily | December 12, 2021

Read More 'RYTM' Stories Here

RYTM Price Returns

1-mo -33.94%
3-mo -30.87%
6-mo -62.09%
1-year -78.38%
3-year -74.73%
5-year N/A
YTD -23.95%
2021 -66.43%
2020 29.49%
2019 -14.58%
2018 -7.50%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7355 seconds.